The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.
(HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at ...
Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.
The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...
The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...
TITUSVILLE, N.J., Jan. 21, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today the U.S. Food and Drug Administration (FDA) approval of a supplemental New Drug Application (sNDA) for ...
An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato ...
In today's Health Alert, the FDA has approved the first stand-alone nasal spray to treat drug-resistant depression.